Jade Biosciences, Inc. Common Stock · XNAS · 131 sessions on record
$14.05▼ −0.13 · −0.9%from $14.18 the session before · Sep 30, 2026 close · end of day
Open
$14.43
High
$14.74
Low
$13.95
Day's range
$0.795.6% of the previous close
VWAP
$14.18close −0.90% from it
Volume, shares
931K0.91× the 20-session average
Traded, $
$13.2M
Trades
10.6K88 shares per trade
Previous close
$14.18−0.13 to the close
Market cap
$893.5Mat the close of Sep 30
Day range13% of the way up
$13.95$14.74
52-week range7% of the way up
$13.04 Mar 30$28.00 Apr 27
−50% from the high · +7.8% from the low
Options
No listed options on JBIO
Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it
consolidated · latest filed Aug 10, 2026 · SEC filings
Profit −$55.8M in the Jun 2026 quarter, consolidated.
Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of JBIO on the consolidated basis with the market's move on the first session after each filing
Quarter
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
Market on the day
Jun 2026filed Aug 10
—
—
−$55.8M
—
-0.76
▲ +2.9%S&P 500 −0.3% · +3.2 pp
Mar 2026filed Aug 10
—
—
−$40.4M
—
-0.57
▲ +2.9%S&P 500 −0.3% · +3.2 pp
Dec 2025filed Mar 6
—
—
−$31.9M
—
10.25
—not reached
Sep 2025filed Nov 14
—
—
−$25.2M
—
-0.48
—not reached
Jun 2025filed Aug 10
—
—
−$32.1M
—
-0.86
▲ +2.9%S&P 500 −0.3% · +3.2 pp
Mar 2025filed Aug 10
—
—
−$38.2M
—
-12.10
▲ +2.9%S&P 500 −0.3% · +3.2 pp
Dec 2024filed Mar 27
—
—
−$5.4M
—
4.41
—not reached
Sep 2024filed Nov 14
—
—
−$16.3M
—
-5.16
—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of JBIO on the consolidated basis, summed from the quarters filed
Year
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
FY25to Dec 2025
—
—
−$127.4M
—
-3.19
FY24to Dec 2024
—
—
−$69.6M
—
-2.44
FY23to Dec 2023
—
—
−$75.5M
—
-2.87
FY22to Dec 2022
—
—
−$51.5M
—
-2.10
FY21to Dec 2021
—
—
−$23.0M
—
-1.87
Fundamentals
consolidated · filings to Jun 2026 · close $14.05 on Sep 30
JBIO trades at 1.7 times trailing earnings against 20 for its industry, 2.0 times book value, market cap $893.5M.
Valuation
Market cap
$893.5Mon Sep 30
Price to earnings
1.7consolidated · four quarters to Jun 2026 · industry 20
Trailing EPS
$8.44diluted · consolidated · four quarters to Jun 2026
Price to book
2.0consolidated · balance sheet to Jun 2026
Book value a share
$6.92consolidated · balance sheet to Jun 2026
Debt to equity
—
Return on equity
-48%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
—
Shares outstanding
63.6Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
—
Revenue growth, 12 months
—
Revenue 3-year CAGR
—trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
−$153.2Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—
PeersPharmaceutical Preparations · the ten largest by market cap · industry P/E 20, market caps over trailing profit of 6 stocks
Stocks in the industry Pharmaceutical Preparations with market cap, price to earnings and price to book
13F managers hold 230% of shares, FMR LLC the largest at 29%, Jupiter Topco LLC 20% and Fairmount Funds Management LLC 14%, as filed for the quarter to Jun 2026.
28.7%19.7%14.3%165.9%
FMR LLC 28.7%
Jupiter Topco LLC 19.7%
Fairmount Funds Management LLC 14.3%
Other 13F managers 165.9%
Held by 13F managers
230%of shares outstanding
Shares held
145M+20% on Mar 2026 among managers filing both
Managers holding
147113 a quarter earlier
Largest holder
29%FMR LLC
Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter
Largest 13F holders of JBIO
Manager
Shares
Of outstanding
Value
Change on quarter
FMR LLC
18.3M
29%
$405.6M
+4.08M
Jupiter Topco LLC
12.5M
20%
$278.7M
—
Fairmount Funds Management LLC
9.11M
14%
$202.4M
unchanged
RA CAPITAL MANAGEMENT, L.P.
7.34M
12%
$163.1M
unchanged
Venrock Adviser, LLC
6.44M
10%
$143.1M
unchanged
Bellevue Group AG
6.12M
9.6%
$135.9M
−887K
Paradigm Biocapital Advisors LP
5.71M
9.0%
$127.0M
—
BlackRock, Inc.
5.6M
8.8%
$124.5M
+975K
FRANKLIN RESOURCES INC
5.58M
8.8%
$124.1M
—
STATE STREET CORP
4.67M
7.3%
$103.8M
+3.36M
Insider tradesSEC Forms 3, 4 and 5 · the latest 4
No open-market insider buying or selling in the last 90 days.
JBIO insider trades
Insider
Trade
Shares
Price
Held after
King Andrew JamesOfficer
granted · Feb 12, 2026
41,250
$0.00
386,113
Frohlich TomDirector,Officer
granted · Feb 12, 2026
78,750
$0.00
86,331
Balta ElizabethOfficer
granted · Feb 12, 2026
28,125
$0.00
28,125
Dahms Bradford D.Officer
granted · Feb 12, 2026
37,813
$0.00
37,813
Corporate actions
exchange records
No corporate action on record for JBIO yet.
Price history
131 sessions on record · to Sep 30 · end of day
JBIO is −33.2% over 20 sessions against the S&P 500's +0.1%, 50% below its 52-week high, realised volatility 59% annualised.
Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
Window
From $
JBIO %
S&P 500 %
Difference pp
120 sessionssince Apr 9
$18.23
▼ −23%
▲ +12%
−35
60 sessionssince Jul 7
$22.45
▼ −37%
▲ +2.0%
−39
20 sessionssince Sep 1
$21.02
▼ −33%
▲ +0.11%
−33
5 sessionssince Sep 23
$14.71
▼ −4.5%
▼ −0.67%
−3.8
1 sessionsince Sep 29
$14.18
▼ −0.92%
▼ −0.21%
−0.71
Averages of the closeclose against each average
5-session average
$14.35close −2.1% from it
20-session average
$17.15close −18% from it
50-session average
$19.69close −29% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$1.17.8% of the close
Average day's range, 20
$0.866.2% of the close
Volume against 20 sessions
0.91×931K vs 1.04M average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
59%≈ ±3.7% a session · moved more than that on 5 of 20
Realised volatility, 60
58%≈ ±3.7% a session · moved more than that on 15 of 60
Beta to S&P 500, 60
1.34moved with S&P 500 on 32 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
7 up · 13 downof 20
Last 60 sessions
26 up · 34 downof 60
Best session, 250
▲ +16%Jun 22
Worst session, 250
▼ −16%Apr 29
Short-sale volume
25 sessions · to Sep 30, 2026
Short sales were 68% of reported volume on Sep 30, 2026, against 55% over the last 25 sessions.
Last 10 sessionsshare of the day's reported volume
Pharmaceutical Preparations · SEC standard industrial classification
SEC CIK
1798749
Sessions on record
131
Price source
End of day · delayed
Computed
1 Oct, 10:41 pm IST
OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.